Drug for the treatment of patients with chronic alcoholism and method of treatment

 

(57) Abstract:

The invention relates to pharmacy and medicine, namely to medicines for the treatment of patients with chronic alcoholism and ways of their treatment. The invention lies in the fact that the medicinal product contains, in addition naltrexone corticosteroids at a certain content of components. As a corticosteroid, preferably use triamcinolone and as a medicinal form - a form for implantation. Also proposed is a method of treating a patient with chronic alcoholism by gradual impact on the patient. The invention provides a more effective treatment of patients with chronic alcoholism (allows to increase the number of patients with onset of remission and prolong periods of remission). 2 S. and 4 C.p. f-crystals.

The invention relates to pharmacy and medicine, in particular to medicines for the treatment of patients with chronic alcoholism and ways of their treatment, which can find application in addiction.

Know the use of tetraethylthiuramdisulphide ("Antabus", "Disulfiram", pills for implantation "Rathter" or "Esperal") for the treatment of chronic alcoholism [1].

Closest to the proposed remedy is the use for the treatment of chronic alcoholism naltrexone in pill or capsule form for oral administration [2].

The disadvantage of this tool is its relatively low efficiency, which may be connected with the comparatively low duration and clinical features of these patients.

There is a method of treatment of patients with chronic alcoholism, which involves the removal of the withdrawal syndrome within 7-15 days and subsequent appointment - naltrexone orally in a daily dose of 50-150 mg every 1-3 days 1.5-3 months [2].

The disadvantage of this known method is the relatively low efficiency (the number of patients with remission and its duration).

The present invention is characterized by the fact that the proposed group of inventions combined to form a single inventive concept.

Offer in accordance with the invention, a drug for the treatment of patients with chronic alcoholism include naltrexone and R> B as corticosteroid usage of triamcinolone. The drug is used in a form for implantation.

A method for the treatment of patients with chronic alcoholism is that the patient detoxification followed by implantation of a drug naltrexone - corticosteroid and psychological rehabilitation of the patient and his entourage.

Practically the method is carried out in three stages as follows:

- stage 1 - detoxification one of the conventional methods such as infusion therapy, hemosorption, plasmapheresis;

- stage 2 - implantation to the patient the above drugs - naltrexone-triamcinolone accepted way for 2-3 months. If necessary, re-implantation, depending on the condition of the patient;

- stage 3 - psychological rehabilitation of the patient and his inner circle, aimed at a deeper study of the psychological side of addiction. At this stage, apply various proven psychological techniques to help the patient to adapt to life without alcohol.

The following examples illustrate proposed by isolatek for implantation.

To 50 C. o'clock naltrexone add 4 C. H. triamcinolone and a sufficient amount of fillers. The resulting mass is pressed and sterilized.

2. The example of the treatment.

Patient B., aged 32, with a diagnosis of Chronic alcoholism 2 tbsp., disease duration 10 years. Three were treated at home and in the hospital at the place of residence using traditional approaches and tools (implantation "esperal", encoding, homeopathy). In each case, the remission period did not exceed 2-4 weeks. With the consent of the patient and his family were treated by the proposed method. After detoxification with the use of infusion therapy to a patient subcutaneously was used naltrexone-triamcinolone. After 7 days the patient was started on a course of psychological rehabilitation, which was carried out within 2 months. Subsequent monitoring of this patient for 10 months showed persistent remission.

In the treatment of 10 patients with chronic alcoholism on the proposed method using the proposed means of a positive effect with duration of remission 6-10 months. was observed in 5 patients (50%).

When treating a known manner with the use of oral forms of naltrexone (Antaxone", Zambon Group only in 3% of cases.

As follows from the above results, the proposed tool has a prolonged effect, and treatment of high clinical efficacy.

Used books

1. Mashkovsky M. D. Medicines.- Kharkov: Torsing, 1997. - 1 o'clock. - S. 226-228.

2. Physician''s Desk Reference. Medical Economics Company, 1998. - Ed. 52. - P. 871.

1. Drug for the treatment of patients with chronic alcoholism on the basis of naltrexone, characterized in that it further comprises a corticosteroid in the following ratio, wt.h.:

Naltrexone - 50 - 100

Corticosteroid - 4 - 8

2. Drug under item 1, characterized in that as corticosteroid use triamcinolone.

3. Drug on PP.1 and 2, characterized in that the use of implantable form.

4. A method of treating a patient with chronic alcoholism by gradual impact on the patient, at the first stage, the detoxification of the body and then implanted drug naltrexone-corticosteroid and then hold the psychological rehabilitation of the patient.

5. The method of treatment according to p. 4, characterized in that the medicinal Method of treatment for PCP. 4 and 5, characterized in that the remission period lengthen the re-introduction of drugs naltrexone-corticosteroid.

 

Same patents:
The invention relates to medicine, namely to addiction
The invention relates to medicine and, in particular, to addiction

Set alcohol funds // 2146529
The invention relates to medicine, namely to biologically active additives used in addiction, for control and treatment status hangover after acute alcohol intoxication, as well as for prevention and treatment of alcoholism
The invention relates to pharmacy and medicine and relates to a medicinal product for the treatment of patients with opiate addiction and their treatment

Drug // 2146129
The invention relates to medicine and relates to a medicinal product containing the packet of the granules for the preparation of effervescent drink acetylsalicylic acid and ascorbic acid

The invention relates to formulations with prolonged release of the active substance containing cisapride-(L)-tartrate, in particular, for oral administration, for use as pharmaceuticals, particularly for the treatment of gastrointestinal diseases

The invention relates to medicine, namely for the preparation of solid dosage forms with controlled release of the active ingredient in accordance with the technology of spray drying and curing inkjet

The invention relates to solid dosage forms, which are characterized by stable release of active substances of alprazolam (chemical formula: 8-chloro-1-methyl-6-phenyl-4H-[1,2,4] triazole[4,3-a][1,4] -benzodiazepine), as well as to a new method of obtaining them

The invention relates to medicine
The invention relates to medicine and relates to a product containing ibuprofen and codeine
The invention relates to pharmacy and medicine and relates to a medicinal product for the treatment of patients with opiate addiction and their treatment

How sedation // 2142736
The invention relates to medicine and can be used in anesthesiology and applies to the conduct of sedation
The invention relates to medicine and relates to a product containing ibuprofen and codeine

The invention relates to medicine, namely to pulmonology, and for the treatment of patients with bronchial asthma
The invention relates to chemical-pharmaceutical industry, namely the production of antitussives
Up!